secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0000950170-24-031448
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences reports 2023 net loss of $101.9M; cash at $201.4M; trial timelines reiterated
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities totaled $201.4M as of Dec 31, 2023, down from $276.6M year-end 2022.
- Net loss for 2023 was $101.9M ($1.40 per share) vs $68.2M ($1.01 per share) in 2022.
- R&D expenses for 2023 increased 68% to $85.7M, driven by PALIZADE, PORTOLA trials and milestone payment to Onyx.
- Restructuring and impairment charges of $6.2M in Q4 2023 from employee termination benefits and asset impairment.
- PALIZADE Phase 2b (lupus nephritis) and PORTOLA Phase 2a (autoimmune hepatitis) enrolling; topline data expected mid-2026 and mid-2025 respectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024031448/0000950170-24-031448-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024031448/kzr-20240314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-031448

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer